A large-scale Phase 3 clinical trial to establish ambroxol’s potential to slow the progression of Parkinson’s disease, will start in early 2023.
Infections treated with specialty hospital care in early- and mid-life are associated with an increased subsequent risk of Alzheimer’s and Parkinson’s diseases, but not amyotrophic lateral sclerosis (ALS), according to a study by researchers from Karolinska Institutet, published in PLOS Medicine.
Adding a few servings of flavonoid-rich foods to their diets a week could be an easy way for people with Parkinson's Disease to help improve their life expectancy, according to the researchers.
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson’s disease. The finding could help explain an earlier outcome of the same study, in which the drug nilotinib was able to halt motor and nonmotor (cognition and quality of life) decline in the long term.
A new discovery by University of Guelph researchers may ultimately help in devising new therapies and improving quality of life for people with Parkinson’s disease.